The mainstreaming of private asset funds is in full swing, but many investors are still confused about what role these products should play in a portfolio. Chris Tate tackles some of the biggest claims being made about semiliquid funds' benefits--from their alleged volatility-smoothing powers to their sometimes eye-popping returns -- and explains what investors should realistically expect when buying one.
Podden och tillhörande omslagsbild på den här sidan tillhör
Morningstar. Innehållet i podden är skapat av Morningstar och inte av,
eller tillsammans med, Poddtoppen.
